Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11993
Peer-review started: August 24, 2022
First decision: September 23, 2022
Revised: September 27, 2022
Accepted: October 19, 2022
Article in press: October 19, 2022
Published online: November 16, 2022
Polycythemia vera (PV), often attributed to the JAK2 V617F mutation, is characterized by enhanced red blood cell counts in the peripheral blood. PV-associated renal disease is clinically rare; to date, there have been reports of other chronic kidney diseases related to PV, but no reports on PV-associated minimal change disease.
A 37-year-old man presented with proteinuria and high red blood cell count on January 4, 2021. The patient underwent bone marrow and renal biopsies, then was subsequently diagnosed with PV and minimal change in disease. Hydroxyurea was administered and proteinuria remission was achieved. The patient’s last visit was on April 14, 2022.
We inferred that there may be a causal relationship between PV and minimal change disease.
Core Tip: Polycythemia vera (PV) is a myeloproliferative neoplasm that can influence the immune system and affect organs such as the kidneys. This is the first report of PV-associated minimal change disease. In our case, hydroxyurea administration was effective and proteinuria remission was achieved. Therefore, we infer there may be a causal relationship between PV and minimal change disease.